In addition to the transcriptional regulatory mechanism of CBFB, we have also demonstrated that RUNX1-p53-CBFB regulatory circuit contributes to the acquisition of treatment resistance of AML cells. This evidence concerns the gene RUNX1 and acute myeloid leukemia.